Vaxart Inc (VXRT) announces a major partnership with Dynavax and reports significant revenue growth, while navigating market ...

Entered into an exclusive license agreement with Dynavax for the Company’s COVID-19 oral pill vaccine candidate for potential cumulative proceeds ...

Entered into an exclusive license agreement with Dynavax for the Company's COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollm ...

The median concentration across all sites in October 2025 was 17.1k copies/gram (cp/g), a decrease of ~74% compared to ...

“The most common point that will generally contain germs are called ‘high-touch areas,’” said Kevin W. Garey, professor and ...

ICMR’s nationwide lab network strengthens outbreak surveillance, detects deadly viruses early, and fortifies the country’s ...

Q3 2025 Management View CEO Steven Lo announced a major partnership with Dynavax, under which Vaxart could receive up to $700 million in license, regulatory, and milestone fees, as well as royalties ...

Vaxart ( ($VXRT) ) has released its Q3 earnings. Here is a breakdown of the information Vaxart presented to its investors. Vaxart, Inc. is a ...

First, the phase 3 trial of Moderna’s norovirus vaccine had to endure a clinical hold. | First, the phase 3 trial of ...

Outbreaks of norovirus, an extremely contagious stomach bug, can spread quickly. “‘Tis the season for germs,” said Dr.

Moderna’s third quarter was shaped by sharply lower demand for COVID-19 vaccines, yet the company delivered results above ...

Dynavax is paying $30 million upfront for global rights to Vaxart’s investigational oral COVID-19 vaccine candidate, positioning the biotech to see phase 2b data before placing a bigger bet on the ...